Alembic gets USFDA nod for generic ophthalmic solution

PTI New Delhi | Updated on April 20, 2020 Published on April 20, 2020

A view of Alembic Pharmaceuticals's plant at Panelav, Gujarat

Alembic Pharmaceuticals on Monday said it had received approval from the US health regulator to market Alcaftadine ophthalmic solution, in the American market.

The company has received tentative approval from the US Food and Drug Administration (USFDA) for its abbreviated new drug application (ANDA) Alcaftadine Ophthalmic Solution, Alembic Pharmaceuticals said in a regulatory filing.

The approved ANDA is therapeutically equivalent to Allergan, Inc’s Lastacaft Ophthalmic Solution, 0.25 per cent.

The product is indicated for the prevention of itching associated with allergic conjunctivitis in the eyes.

According to IQVIA data, Alcaftadine has an estimated market size of USD 7 million for twelve months ending December 2019.

Alembic said it has now a cumulative total of 120 ANDA approvals from the USFDA.

Follow us on Telegram, Facebook, Twitter, Instagram, YouTube and Linkedin. You can also download our Android App or IOS App.

Published on April 20, 2020
This article is closed for comments.
Please Email the Editor